Nascent Biotech Receives One Million Dollar Commitment From TRITON FUNDS LP
September 11 2019 - 8:53AM
InvestorsHub NewsWire
Nascent Biotech Receives One Million Dollar Commitment From TRITON
FUNDS LP
SAN DIEGO, CA -- September 11, 2019 -- InvestorsHub NewsWire --
Nascent Biotech, Inc. (OTCQB:NBIO), a biopharmaceutical
company focusing on the development of monoclonal antibodies for
the treatment of various types of cancers, announces an agreement
with TRITON FUNDS LP. TRITON FUNDS LP will invest $1 million to
support the commencement of Phase I human clinical studies on
Nascent’s primary asset, Pritumumab.
“We are dedicated to our ongoing efforts to bring our brain
cancer drug to patients by completing the first milestone of
initiating phase I human clinical trials,” said Sean Carrick,
President and CEO. “Triton’s investment will allow us to
begin our clinical trial plus complete the numerous testing steps
required by the FDA. Triton’s confidence in this very
promising project will help address an unmet need in helping brain
cancer patients alongside eliminating the going concern from our
financials.”
“Brain cancer is a severely underserved market affecting up to
25,000 new patients annually in the US alone. The metastatic
patient population adds an additional 175,000 patients. We
are excited to finally begin treating patients,” added Mr. Carrick.
“Pritumumab addresses an unmet need in brain cancer and may have
broader applications in other epithelial cancers such as pancreas,
lung and breast, as well. We are fully committed to advancing
this promising drug through the regulatory process and positively
impacting the treatment of difficult to treat cancers.”
About Nascent Biotech Inc
Nascent Biotech, Inc is a clinical-stage biotech company engaged
in the development of monoclonal antibodies to be used in the
treatment of various cancers. Its products are not
commercially available. For further information please visit our
website www.nascentbiotech.com.
About TRITON FUNDS LLC
TRITON FUNDS LLC is the largest student-run fund-manager in the
USA. Founded by undergraduates from the University of
California, San Diego, TRITON FUNDS provides students the
invaluable opportunity to gain real-world experience investing
alongside experienced financial professionals. It invests in high
performing teams with revolutionary aspirations to grow their
company into industry leaders. TRITON FUNDS creates an ecosystem
that assists talented entrepreneurs in successfully growing their
ideas and maintaining strong community ethical standards. It
provides strategic capitalization, business development support,
and engineered exits to organizations that have a viable future in
the modern economy. More information can be found
at http://www.tritonfunds.com.
Safe Harbor:
Statements in this press release about our future expectations
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and our actual results could differ materially
from expected results. These risks and uncertainties include,
without limitation, Nascent Biotech Inc's ability to target the
medical professionals; Nascent Biotech Inc's ability to raise
capital; as well as other risks. Additional information about
these and other factors may be described in the Nascent Biotech
Inc's Form 10, filed on May 2, 2015, and future subsequent filings
with the Securities and Exchange Commission. The Company
undertakes no obligation to update or release any revisions to
these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Contact:
Sean Carrick
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
Nascent Biotech (QB) (USOTC:NBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nascent Biotech (QB) (USOTC:NBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024